Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

Clinician EHR Alerts Lead to Speedier Evaluation, Treatment of Valve Disease

News Conference News ACC 2026

Clinician EHR Alerts Lead to Speedier Evaluation, Treatment of Valve Disease

April 01, 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

News Conference News ACC 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Yael L. Maxwell

March 30, 2026

Transcatheter ViV a Solid Option for Failed Mitral Bioprostheses: SURViV

News Conference News ACC 2026

Transcatheter ViV a Solid Option for Failed Mitral Bioprostheses: SURViV

March 30, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

April 10, 2025

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

News Conference News ACC 2025

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

April 07, 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

What’s Going to Be Hot at ACC 2025?

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England

News Conference News ACC 2024

TAVI, SAVR Rates Roughly Equal for Patients Younger Than 65 in New England

Yael L. Maxwell

April 05, 2024

What’s Going to Be Hot at ACC 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

April 01, 2024

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

News Conference News ACC 2020

Early Data Support TAVR in Bicuspid Valves, but Questions Remain

Michael O'Riordan

March 29, 2020

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

News Conference News ACC 2019

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Yael L. Maxwell

March 17, 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

March 11, 2019

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

News Conference News ACC 2018

Urgent/Emergent TAVR: Risky but Rewarding, TVT Registry Data Hint

March 19, 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

March 10, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.